Disease Information

General Information of the Disease (ID: DIS00222)

• Name: Inflammatory myofibroblastic tumor
• ICD: ICD-11: 2E92

Type(s) of Resistant Mechanism of This Disease

  ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Drug

Approved Drug(s) 1 drug(s) in total

Alectinib

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: ALK tyrosine kinase receptor (ALK) [1]

• Resistant Disease: Inflammatory myofibroblastic tumor [ICD-11: 2E92.1]
• Molecule Alteration: Missense mutation; p.L1196Q
• Resistant Drug: Alectinib
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: qRT-PCR
• Mechanism Description: A novel, secondary mutation in ALK exon 23 (L1196Q) was identified in patient 1 after alectinib resistance developed.

Key Molecule: ALK tyrosine kinase receptor (ALK) [1]

• Resistant Disease: Inflammatory myofibroblastic tumor [ICD-11: 2E92.1]
• Molecule Alteration: Missense mutation; p.L1196Q
• Resistant Drug: Alectinib
• Experimental Note: Identified from the Human Clinical Data
• Experiment for Molecule Alteration: qRT-PCR
• Mechanism Description: A novel, secondary mutation in ALK exon 23 (L1196Q) was identified in patient 1 after alectinib resistance developed.

References

• Ref 1: Efficacy and Resistance of ALK Inhibitors in Two Inflammatory Myofibroblastic Tumor Patients with ALK Fusions Assessed by Whole Exome and RNA Sequencing .Onco Targets Ther. 2020 Oct 13;13:10335-10342. doi: 10.2147/OTT.S270481. eCollection 2020. 10.2147/OTT.S270481